Red Microalga Boosts Ciprofloxacin Against Gut Superbugs

In a finding that could reshape how scientists think about fighting drug-resistant gut infections, researchers in Brazil have shown that a humble red microalga long prized for its nutritional chemistry can dramatically strengthen one of the world’s most widely used antibiotics. The lipid extract of Porphyridium purpureum, a single-celled Rhodophyte grown in photobioreactors, failed to kill pathogenic intestinal bacteria on its own, yet when paired with ciprofloxacin it cut the amount of drug needed to inhibit Salmonella Typhimurium and Escherichia coli by up to seventy-five percent. The study, published in Frontiers in Natural Products, offers a fresh candidate for a strategy that public health experts regard as critical: reviving existing antibiotics rather than waiting for entirely new ones.

The stakes could hardly be higher. Antimicrobial resistance is one of the most severe public health threats of the twenty-first century. According to the Global Burden of Bacterial Antimicrobial Resistance report cited by the authors, resistance was associated with roughly 4.95 million deaths in 2019, with 1.27 million directly attributable to resistant pathogens. Projections warn that without effective countermeasures, annual deaths linked to bacterial resistance could approach ten million by 2050. Compounding the problem, the pipeline of genuinely novel antibiotics has slowed dramatically, and many compounds in development offer little advantage against Gram-negative bacteria, whose double-layered cell envelope is notoriously effective at excluding drugs.

The intestinal microbiota sits at the heart of this crisis. This complex ecosystem of commensal and symbiotic bacteria supports digestion, immunity, metabolism, and the integrity of the intestinal barrier, but it can also serve as a vast reservoir of resistance genes. Overuse and inappropriate use of antibiotics disturb this balance, a state known as dysbiosis, exerting selective pressure that favors resistant organisms and promotes the horizontal transfer of resistance genes between species. Pathogens such as E. coli, Salmonella species, and Enterococcus faecalis can then exploit this disrupted environment, causing illnesses that range from gastrointestinal distress to life-threatening sepsis. Any intervention that allows lower antibiotic doses, the researchers reason, could help reduce that selective pressure.

Enter Porphyridium purpureum. This red microalga has attracted sustained biotechnological interest because it thrives in both marine and freshwater environments and manufactures an impressive portfolio of bioactive molecules, including sulfated exopolysaccharides, phycobiliproteins, and fatty acids. Its polyunsaturated fatty acids, particularly arachidonic acid and eicosapentaenoic acid, have previously been linked to antimicrobial effects through disruption of bacterial cytoplasmic membranes. Because fatty acids can destabilize the plasma membrane, interfere with the electron transport chain, and impair bacterial enzymatic metabolism, the team suspected that the lipid fraction of the alga might hold untapped therapeutic potential.

To find out, the researchers cultivated the microalga in a fifteen-liter bubble column photobioreactor under tightly controlled conditions: artificial seawater enriched with F/2 medium, a temperature of 25 degrees Celsius, and a twelve-hour light and dark cycle. Biomass was harvested at a standardized optical density and subjected to exhaustive percolation extraction with chloroform, a solvent highly efficient at solubilizing nonpolar lipids. The process yielded a total lipid fraction of sixteen percent of the dry biomass. A parallel extraction protocol, using cold ethanol precipitation and ultrasonication, recovered exopolysaccharides at a yield of 841.7 milligrams per liter of culture.

Gas chromatography coupled with mass spectrometry then revealed the chemical identity of the lipid fraction. After derivatization into fatty acid methyl esters, seven compounds were identified, dominated by methyl palmitate at 42.05 percent, methyl arachidonate at 22.73 percent, and methyl linoleate at 17.91 percent, followed by methyl eicosapentaenoate at 8.64 percent and smaller amounts of methyl oleate, methyl alpha-linolenate, and methyl stearate. This profile, rich in both saturated and polyunsaturated fatty acids, closely matches previous characterizations of the species and underscores its reputation as an exceptional natural accumulator of arachidonic acid, a distinction the authors attribute to the alga’s predominantly omega-6 biosynthetic pathway.

The antimicrobial results delivered an unexpected twist. Tested alone at concentrations from 800 down to 6.25 micrograms per milliliter, neither the lipid extract nor the exopolysaccharides inhibited growth of E. coli, Salmonella enterica serovar Typhimurium, or Enterococcus faecalis in standard broth microdilution assays. But the checkerboard combination assays told a different story. At just 6.25 micrograms per milliliter, the extract lowered the ciprofloxacin minimum inhibitory concentration against Salmonella Typhimurium from 4 to 1 microgram per milliliter, producing a fractional inhibitory concentration index of 0.26, well below the 0.5 threshold that defines synergism. Against E. coli, 12.5 micrograms per milliliter of extract reduced the ciprofloxacin MIC from 4 to 2 micrograms per milliliter, an index of exactly 0.50. No synergism appeared when the extract was combined with ampicillin against E. faecalis, although the authors caution that the different antibiotic used for that Gram-positive organism makes it impossible to attribute the difference solely to cell envelope architecture.

The proposed mechanism centers on membrane chemistry. Polyunsaturated fatty acids, with their multiple double bonds, are more fluid than saturated analogs and interact more readily with bacterial membranes, potentially opening transient channels that allow antibiotics to penetrate the cell interior. Prior studies support this idea: arachidonic acid combined with gentamicin slashed the drug’s MIC against Staphylococcus aureus from roughly 37 to 1.7 micrograms per milliliter, and combinations of eicosapentaenoic or alpha-linolenic acid with neomycin produced similar synergy. Comparable effects have been reported for medium-chain fatty acids paired with levofloxacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. coli. The Brazilian team suggests that the synergy observed here likely reflects the combined action of multiple lipid constituents rather than a single fatty acid, and that the extract may be functioning as an antibiotic adjuvant, a compound with little intrinsic killing power that nonetheless amplifies the effect of a co-administered drug.

Crucially, the extract also demonstrated an encouraging safety profile. In Vero monkey kidney cells exposed for twenty-four hours to concentrations ranging from 200 to 1600 micrograms per milliliter, the fifty percent inhibitory concentration came out at 1149.21 micrograms per milliliter, indicating low cytotoxicity. Dividing that value by the synergistic combination MICs yields selectivity indices of 183.8 against Salmonella Typhimurium and 91.9 against E. coli, far above the threshold of ten typically regarded as a favorable in vitro safety margin. The authors suggest that this selectivity may arise from fundamental differences between bacterial and mammalian cells: eukaryotic membranes contain cholesterol, which stabilizes the bilayer, whereas bacteria rely on peptidoglycan and, in Gram-negative species, an outer membrane rich in lipopolysaccharides and porins whose composition and charge may render them more vulnerable to bioactive lipids.

The work is emphatically preliminary. The assays used single reference strains rather than clinical isolates, the active molecules responsible for the synergy remain unidentified, and the suspected membrane-permeabilizing mechanism has not been directly demonstrated. Susceptibility categories of the tested strains, moreover, did not formally shift, remaining resistant for Salmonella and intermediate for E. coli despite the MIC reductions. Still, the implications are striking. A sustainably cultivable microalga, grown from a single batch in a standard photobioreactor, appears to harbor a lipid cocktail that could make existing fluoroquinolones more potent at lower doses. If subsequent studies isolate the responsible fatty acids, confirm the mechanism, and validate the effect across diverse clinical isolates, the gelatinous red cells of Porphyridium purpureum may find a second career not as a nutritional supplement, but as a chemical ally in the desperate race to preserve the usefulness of the antibiotics we already have.

Subject of Research: Antibiotic adjuvant potential of fatty acids from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria

Article Title: Fatty acid profile and antimicrobial activity of chloroform extracts from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria

Article References: Popiorek dos Santos, N., Baptista, R. M., Kubelka, B. G., Montes D’Oca, M. G., Thais de Lima, J., Bueno, D. T., Leitzke, A. F., & Ramos, D. F. (2026). Fatty acid profile and antimicrobial activity of chloroform extracts from the red microalga Porphyridium purpureum against pathogenic intestinal bacteria. Frontiers in Natural Products, 5, Article 1884549. https://doi.org/10.3389/fntpr.2026.1884549

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1884549

Keywords: Porphyridium purpureum, microalgae, antimicrobial resistance, ciprofloxacin, fatty acids, antibiotic adjuvant, synergy, Salmonella Typhimurium, Escherichia coli, gut microbiota, lipid extract, cytotoxicity